Holen Sie sich die Stockscreener-App
231.88
1.32%
3.02
Handel nachbörslich:
231.88
Schlusskurs vom Vortag:
$228.86
Offen:
$229.24
24-Stunden-Volumen:
465.80K
Relative Volume:
0.91
Marktkapitalisierung:
$8.98B
Einnahmen:
$1.24B
Nettoeinkommen (Verlust:
$42.23M
KGV:
218.75
EPS:
1.06
Netto-Cashflow:
$150.33M
1W Leistung:
-1.92%
1M Leistung:
-9.73%
6M Leistung:
-15.94%
1J Leistung:
+20.61%
1-Tages-Spanne:
$229.24
$232.91
1-Wochen-Bereich:
$226.66
$240.19
52-Wochen-Spanne:
$148.00
$310.00
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Vergleichen Sie PEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
231.88 | 9.16B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Is Penumbra Inc. a good long term investmentFree Stock Chart Pattern Guide - jammulinksnews.com
Penumbra Inc. Stock Analysis and ForecastPhenomenal returns - jammulinksnews.com
What analysts say about Penumbra Inc. stockExplosive capital gains - jammulinksnews.com
Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025 - Eastern Progress
What drives Penumbra Inc. stock priceBreakthrough profits - jammulinksnews.com
Penumbra, Inc.'s (NYSE:PEN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - simplywall.st
Penumbra's Strategic Growth Potential Bolstered by Upcoming Thunderbolt System Launch and Aspiration Technology Innovation - AInvest
Penumbra CEO's Stock Sale: A Routine Maneuver or Cause for Concern? - AInvest
Penumbra Insider Sold Shares Worth $3,896,344, According to a Recent SEC Filing - MarketScreener
Penumbra CEO Elsesser sells $3.89m in shares By Investing.com - Investing.com Nigeria
Penumbra CEO Elsesser sells $3.89m in shares - Investing.com Australia
NeoGenomics, RadNet, Pediatrix Medical Group, Penumbra, and Neogen Shares Plummet, What You Need To Know - Yahoo Finance
Penumbra (PEN) Announces Completion of Enrollment in STORM-PE Clinical Trial - Insider Monkey
Penumbra (PEN) Sees Price Target Reduction by Citi Ahead of Earnings | PEN Stock News - GuruFocus
Penumbra, Inc.'s (NYSE:PEN) P/S Still Appears To Be Reasonable - 富途牛牛
Insider Sell: Johanna Roberts Sells 600 Shares of Penumbra Inc (PEN) - GuruFocus
Penumbra EVP Roberts sells $151k in company stock By Investing.com - Investing.com Canada
Penumbra EVP Roberts sells $151k in company stock - Investing.com
Penumbra Inc EVP Sells 571 Shares for $144,143.47 on July 1, 2025. - AInvest
Penumbra CEO Adam Elsesser sells $4m in stock on June 25 - Investing.com Nigeria
Penumbra: AI Meets AspirationWhy The Stock Is A Structural Winner - Seeking Alpha
Thrombectomy Devices Market | Advancing Stroke Treatment & Clot - openPR.com
The Top 5 Analyst Questions From Penumbra’s Q1 Earnings Call - Yahoo Finance
Insider Selling: Bridget O'Rourke Sells Shares of Penumbra Inc (PEN) - GuruFocus
Penumbra director O’Rourke sells $12988 in stock - Investing.com
Inquis, Penumbra advance thrombectomy treatments - BioWorld MedTech
Transcript : Penumbra, Inc. Presents at 2025 Truist Securities MedTech Conference, Jun-17-2025 10 - MarketScreener
Penumbra, Inc. Announces Completion of Enrollment for Landmark S - GuruFocus
Penumbra Completes Enrollment for STORM-PE Randomized Controlled Trial - Diagnostic and Interventional Cardiology
Penumbra completes enrollment in pulmonary embolism trial - MassDevice
Penumbra's Revolutionary PE Treatment Trial Hits 100-Patient Mark, Results Could Transform Blood Clot Care - Stock Titan
Clot Management Devices Market Set to Witness Significant - openPR.com
PEN Stock Rises Following the Launch of Ruby XL System - MSN
RSI Alert: Penumbra (PEN) Now Oversold - Nasdaq
Zacks Industry Outlook Penumbra, Integer and AngioDynamics - Yahoo Finance
Penumbra Introduces the Ruby XL System – the Longest, Largest, and Softest Coil on the Market for Vascular Embolization - HMP Global Learning Network
Penumbra Introduces the Ruby® XL Systemthe Longest, Largest, and Softest Coil on the Market for Vascular Embolization - StreetInsider
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):